ImmunityBio (IBRX) said Thursday that the UK's Medicines and Healthcare Products Regulatory Agency accepted its marketing authorization application for Anktiva in combination with bacillus Calmette-Guerin to treat certain patients with non-muscle invasive bladder cancer.
The application covers patients who do not respond to bacillus Calmette-Guerin and are with carcinoma in situ with or without papillary tumors, the company said.
Shares of the company were up 2.8% in recent trading.
Price: 3.33, Change: +0.09, Percent Change: +2.81
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.